Display options
Cite
Milani M, Jha G, Potter DA. Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women. Clin Med Ther. 2009;1:141-156doi: 10.4137/cmt.s9.
Milani, M., Jha, G., & Potter, D. A. (2009). Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women. Clinical medicine. Therapeutics, 1141-156. https://doi.org/10.4137/cmt.s9
Milani, Monica, et al. "Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women." Clinical medicine. Therapeutics vol. 1 (2009): 141-156. doi: https://doi.org/10.4137/cmt.s9
Milani M, Jha G, Potter DA. Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women. Clin Med Ther. 2009 Mar 31;1:141-156. doi: 10.4137/cmt.s9. PMID: 19794821; PMCID: PMC2753667.
Copy Download .nbib Format: NLM
Share it on

Clin Med Ther. 2009 Mar 31;1:141-156. doi: 10.4137/cmt.s9.

Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women.

Clinical medicine. Therapeutics

Monica Milani, Gautam Jha, David A Potter

Affiliations

  1. Department of Medicine, Division of Hematology Oncology and Transplantation, University of Minnesota, Minneapolis, MN, U.S.A.

PMID: 19794821 PMCID: PMC2753667 DOI: 10.4137/cmt.s9

Abstract

The majority of breast cancers express the estrogen receptor and depend on estradiol (E2) for their growth. Hormonal therapy aims at depriving estrogen signaling either by using selective estrogen receptor modulators (SERM)-that interfere with the binding of E2 to its receptor (ER)-or aromatase inhibitors (AI)-that block the aromatase-dependent synthesis of E2. While SERMs are recommended for both pre- and post-menopausal patients, AIs are indicated only for post-menopausal patients. For the past 20 years, the SERM tamoxifen has been considered the "gold standard" for the treatment of hormone receptor positive breast cancers. However, tamoxifen's role is now challenged by third generation AIs, such as anastrozole, which exhibit greater efficacy in the adjuvant setting in several recently reported trials. This review will focus on anastrozole's mechanism of action, dosing, pharmacology, pharmacokinetics, and clinical applications. It will briefly discuss the clinical trials that determined anastrozole's efficacy in the treatment of advanced breast cancer (ABC) and in the neoadjuvant setting. Finally, it will present the clinical trials that established anastrozole as a frontline agent in the treatment of post-menopausal women with hormone receptor positive early breast cancer.

References

  1. Clin J Oncol Nurs. 2004 Feb;8(1):87-8 - PubMed
  2. Oncology. 2005;69(6):471-7 - PubMed
  3. Ann Oncol. 2007 Jul;18(7):1133-44 - PubMed
  4. J Clin Oncol. 2005 Aug 1;23(22):5138-47 - PubMed
  5. Ann N Y Acad Sci. 1994 Sep 30;734:310-21 - PubMed
  6. Ann Oncol. 2007 Apr;18 Suppl 2:ii5-8 - PubMed
  7. J Clin Oncol. 2000 Jun;18(11):2234-44 - PubMed
  8. J Clin Oncol. 2007 Jul 1;25(19):2664-70 - PubMed
  9. Cancer. 2008 Feb 1;112(3 Suppl):695-699 - PubMed
  10. J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):97-101 - PubMed
  11. Lancet. 2005 Aug 6-12;366(9484):455-62 - PubMed
  12. Ann N Y Acad Sci. 2004 Dec;1028:247-57 - PubMed
  13. Cancer Res. 1994 Oct 1;54(19):5092-5 - PubMed
  14. Arthritis Rheum. 2005 Sep;52(9):2594-8 - PubMed
  15. Ann N Y Acad Sci. 1996 Apr 30;784:314-24 - PubMed
  16. N Engl J Med. 1981 Sep 3;305(10):545-51 - PubMed
  17. Pharmacogenetics. 1996 Feb;6(1):1-42 - PubMed
  18. Ann Surg Oncol. 2008 Mar;15(3):691-703 - PubMed
  19. J Clin Oncol. 2008 Apr 1;26(10):1664-70 - PubMed
  20. Lancet Oncol. 2006 Aug;7(8):633-43 - PubMed
  21. Clin Cancer Res. 2001 May;7(5):1230-6 - PubMed
  22. Drugs. 2008;68(9):1319-40 - PubMed
  23. Lancet. 2002 Jun 22;359(9324):2131-9 - PubMed
  24. Lancet. 2005 May 14-20;365(9472):1687-717 - PubMed
  25. Cancer. 2007 Jul 15;110(2):244-54 - PubMed
  26. Eur J Cancer. 2003 Aug;39(12):1684-9 - PubMed
  27. Br J Cancer. 2002 Oct 21;87(9):950-5 - PubMed
  28. Ann Oncol. 2006 Jun;17 Suppl 7:vii10-4 - PubMed
  29. Cancer Invest. 2007 Mar;25(2):102-5 - PubMed
  30. N Engl J Med. 2004 Mar 11;350(11):1081-92 - PubMed
  31. Drug Metab Dispos. 1997 May;25(5):598-602 - PubMed
  32. J Natl Cancer Inst. 2001 May 2;93(9):684-90 - PubMed
  33. J Clin Oncol. 2005 Aug 1;23(22):5108-16 - PubMed
  34. Breast. 2007 Aug;16(4):436-9 - PubMed
  35. J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):175-9 - PubMed
  36. Ann Surg. 1978 May;187(5):475-84 - PubMed
  37. Lancet Oncol. 2008 Jan;9(1):45-53 - PubMed
  38. Ther Clin Risk Manag. 2008 Feb;4(1):189-204 - PubMed
  39. Breast Cancer Res Treat. 2008 Sep;111(2):191-202 - PubMed
  40. J Bone Miner Res. 1997 Sep;12(9):1416-23 - PubMed
  41. J Clin Oncol. 2005 Jan 20;23(3):619-29 - PubMed
  42. Br J Cancer. 1996 Feb;73(4):543-8 - PubMed
  43. Am J Health Syst Pharm. 1998 Mar 1;55(5):445-52 - PubMed
  44. Cancer. 1998 Sep 15;83(6):1142-52 - PubMed
  45. CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 - PubMed
  46. Breast Cancer Res Treat. 2006 Dec;100(3):273-84 - PubMed
  47. Br J Cancer. 1996 Oct;74(8):1286-91 - PubMed
  48. Cancer. 1980 Aug 15;46(4 Suppl):1066-74 - PubMed
  49. Cancer. 2006 May 15;106(10):2095-103 - PubMed
  50. Br J Cancer. 2005 May 9;92(9):1621-5 - PubMed
  51. Clin Cancer Res. 2003 Jan;9(1 Pt 2):468S-72S - PubMed
  52. Breast. 2006 Jun;15(3):430-6 - PubMed
  53. J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64 - PubMed
  54. N Engl J Med. 2005 Dec 29;353(26):2747-57 - PubMed
  55. J Clin Oncol. 2000 Nov 15;18(22):3748-57 - PubMed
  56. J Natl Cancer Inst. 2005 Sep 7;97(17):1262-71 - PubMed
  57. J Clin Oncol. 2004 Nov 1;22(21):4261-71 - PubMed
  58. J Steroid Biochem Mol Biol. 2002 Feb;80(2):163-74 - PubMed
  59. J Clin Oncol. 2003 Jun 1;21(11):2101-9 - PubMed
  60. J Natl Cancer Inst. 1996 Nov 6;88(21):1529-42 - PubMed
  61. Endocr Rev. 1995 Oct;16(5):559-89 - PubMed
  62. Lancet Oncol. 2006 Dec;7(12):991-6 - PubMed
  63. Lancet. 2005 Jan 1-7;365(9453):60-2 - PubMed
  64. J Clin Oncol. 2008 Mar 1;26(7):1059-65 - PubMed
  65. J Clin Oncol. 2008 Jul 1;26(19):3120-1 - PubMed
  66. Clin Cancer Res. 2008 Feb 1;14(3):811-6 - PubMed
  67. Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1049s-1055s - PubMed
  68. J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):477-86 - PubMed
  69. Drugs. 2002;62(17):2483-90; discussion 2491-2 - PubMed
  70. Clin Cancer Res. 2008 Dec 15;14(24):8027-41 - PubMed
  71. Cancer. 2006 Jun 15;106(12):2576-82 - PubMed
  72. J Clin Oncol. 2005 Aug 1;23(22):5178-87 - PubMed
  73. Ann Oncol. 2001 Nov;12(11):1539-43 - PubMed
  74. Biomed Pharmacother. 2003 Dec;57(10):460-2 - PubMed
  75. J Clin Oncol. 2000 Nov 15;18(22):3758-67 - PubMed
  76. Br J Cancer. 2008 May 6;98(9):1494-9 - PubMed
  77. J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53 - PubMed
  78. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1055-9 - PubMed
  79. Endocr Relat Cancer. 2004 Dec;11(4):643-58 - PubMed
  80. J Clin Endocrinol Metab. 1978 Jan;46(1):146-52 - PubMed
  81. J Cancer Surviv. 2007 Dec;1(4):283-91 - PubMed
  82. Endocrinology. 2001 Nov;142(11):4589-94 - PubMed
  83. Cancer Treat Rev. 2008 May;34(3):275-82 - PubMed
  84. Cancer Res. 1998 Mar 1;58(5):927-32 - PubMed
  85. Adv Exp Med Biol. 2008;630:206-19 - PubMed
  86. Mutat Res. 2008 Mar 12;651(1-2):46-55 - PubMed
  87. J Clin Oncol. 1996 Oct;14(10):2738-46 - PubMed
  88. Cancer Res. 2005 Dec 1;65(23):11071-82 - PubMed
  89. Cancer. 1979 Jun;43(6):2207-14 - PubMed
  90. J Clin Endocrinol Metab. 1978 Dec;47(6):1257-65 - PubMed

Publication Types

Grant support